NCT01561079View on ClinicalTrials.gov

Fetal and Infant Effects of Maternal Buprenorphine Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Neonatal Abstinence Syndrome
Interventions
DRUG

Buprenorphine

Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.

Trial Locations (2)

21224

Center for Addiction and Pregnancy, Baltimore

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT01561079 - Fetal and Infant Effects of Maternal Buprenorphine Treatment | Biotech Hunter | Biotech Hunter